Interferon-β-1a inhibition of severe acute respiratory syndrome-coronavirus 2 in vitro when administered after virus infection

Nicola Clementi, Roberto Ferrarese, Elena Criscuolo, Roberta Antonia Diotti, Matteo Castelli, Carolina Scagnolari, Roberto Burioni, Guido Antonelli, Massimo Clementi, Nicasio Mancini

Research output: Contribution to journalArticlepeer-review

Abstract

The ongoing coronavirus disease 2019 pandemic has forced the clinical and scientific community to try drug repurposing of existing antiviral agents as a quick option against severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2). Under this scenario, interferon (IFN) β-1a, whose antiviral potential is already known, and which is a drug currently used in the clinical management of multiple sclerosis, may represent as a potential candidate. In this report, we demonstrate that IFN-β-1a was highly effective in inhibiting in vitro SARS-CoV-2 replication at clinically achievable concentration when administered after virus infection.

Original languageEnglish
Pages (from-to)722-725
Number of pages4
JournalJournal of Infectious Diseases
Volume222
Issue number5
DOIs
Publication statusPublished - Sep 1 2020

Keywords

  • COVID-19 clinical trial
  • IFN-β-1a
  • SARS-CoV-2

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint Dive into the research topics of 'Interferon-β-1a inhibition of severe acute respiratory syndrome-coronavirus 2 in vitro when administered after virus infection'. Together they form a unique fingerprint.

Cite this